Navigation Links
Vermillion Appoints Dr. Eric Varma to its Board of Directors
Date:9/16/2013

AUSTIN, Texas, Sept. 16, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, today announced the appointment of Eric Varma, M.D. to its board of directors.

"As a partner at Oracle Investment Management, Vermillion's largest shareholder, and a physician, Eric brings significant financial and commercial experience in the life sciences to our board of directors," said Thomas McLain, Vermillion's president and CEO. "His expertise will help guide the company as it continues to focus on its novel, high-value diagnostic test, OVA1® and improving the care for women with gynecological cancers."

Dr. Varma is currently a partner at Oracle Investment Management, which is a fundamental research driven investment management company that is exclusively focused on the global health care and bioscience industries. Prior to joining Oracle Investment Management, he worked at Leerink Swann, the Boston Consulting Group, and the Food and Drug Administration. Dr. Varma received his B.A. from the University of California Berkeley, M.D. from the Albert Einstein College of Medicine, and M.B.A. from the MIT Sloan School of Management.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an i
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
2. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
3. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
4. Vermillion Reports Fourth Quarter and Full Year 2012 Results
5. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
6. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
7. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
8. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
9. Vermillion Reports Third Quarter 2012 Results
10. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
11. Vermillion to Present at the 2012 Gateway Conference on September 6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 The National Space Biomedical ... Center for Space Radiation Research (CSRR) under the leadership ... an Associate Professor of Pharmaceutical Sciences within the University ... Division of Radiation Health. She is located in ... a team of investigators working across four U.S. institutions, ...
(Date:7/22/2014)... , July 22, 2014  Decision Resources Group finds that ... Canada will remain relatively stagnant at a value ... fact that percutaneous coronary intervention (PCI) volumes are growing faster ... markets, such as the United States ... largely driven by the increase in penetration of PCI procedures ...
(Date:7/22/2014)... July 22, 2014  Decision Resources Group finds ... (MS) patients currently treated with Biogen Idec,s ... experienced flushing and/or gastrointestinal events while on ... currently experiencing these side effects, signifying either ... management of such events. In the end, ...
Breaking Medicine Technology:Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3
... 14 New England Biolabs (NEB) has launched ... to simplify DNA methylation analysis for epigenetics researchers. ... of the current methods, including the lack of ... of 5-hydroxymethlcytosine (5-hmC) in the epigenome. ...
... Fe and Femcon® Fe... -- ARDEE, Ireland, Oct. 14 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome 2Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 2Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 3Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 4Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 5Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 6Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 7Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 8Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 9Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 10
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will serve ... for the 2014-2015 fiscal year. He joined the Board ... "“Serving on the HASA board has given me a broader, ... remember how much others need help." , ABOUT AARON MARSHALL:, ... a B.S. in Finance from the University of Delaware. Currently, ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor ... Los Angeles with the 2014 E. Donnall Thomas ... the discovery of the iron-regulatory hormone hepcidin and investigation ... after the Nobel Prize Laureate and past Society president ... hematology that have represented a paradigm shift or significant ...
(Date:7/22/2014)... Robert E. Marc, Ph.D., director of research at the ... been named by the International Society of Eye Research ... Research Foundation,s 2014 Paul Kayser International Award in Retina ... scientist who has made a significant contribution to the ... being presented this week at the ISER Biennial Meeting ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
(Date:7/22/2014)... Latin American Conference on Lung Cancer (LALCA 2014) will ... Peru. , Lung Cancer is still the leading cause ... Building on the success of the previous conferences in ... will discuss the science and advances in the treatment ... and Latin America in particular. , With tobacco being ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... human body, HOUSTON, Sept. 25 Can you ... Simply visit The John P. McGovern Museum of Health ... explore the latest,exhibit -- Sesame Street Presents: The Body ... October 4, 2007 and January 13, 2008.,The exhibit offers ...
... 25 A Place for Mom, the nation,s largest,referral ... that John,Temple, Chief Operating Officer was named to the ... The 40 Under 40 List is the Pacific Northwest ... They look for,nominees that work hard to drive the ...
... Phase II data presented today suggest that ZD4054, a ... with Hormone Resistant Prostate Cancer (HRPC), could offer a ... HRPC who were asymptomatic or mildly symptomatic for pain.1 ... percent reduction in the risk of death compared to ...
... 25 ThermoSpas, the country,s,largest hot tub retailer, ... chronically,ill children to give specially-designed therapeutic hot tubs ... program, the company will donate 12,ThermoSpas hot tubs ... who will benefit,from warm water therapy. ThermoSpas encourages ...
... Continuum Health Partners Selects Ericom(R) PowerTerm(R) WebConnect for ... ... 25 Continuum Health Partners, a,New York-based non-profit hospital system, ... of Continuum,s strategy to,provide doctors and staff with secure, on-demand ...
... youngsters to stay healthy, , , TUEDAY, Sept. 25 (HealthDay News) ... and way too much junk food are pushing U.S. children ... new studies finds. , The studies -- published in a ... -- show the myriad challenges youngsters face every day ...
Cached Medicine News:Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 2Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 3Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 4Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 5Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 6Health News:A Place for Mom COO Makes Seattle's 40 Under 40 List 2Health News:Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054 2Health News:Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054 3Health News:Photos: America's Chronically Ill Children Have New Hope with 'Hot' Gift 2Health News:Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization 2Health News:Junk Food, TV Driving Kids to Obesity 2Health News:Junk Food, TV Driving Kids to Obesity 3Health News:Junk Food, TV Driving Kids to Obesity 4
... Laboratories offers a comprehensive line of pregnancy ... and urine in convenient one-step stick and ... testing options. Clearview Easy HCG is a ... stick format. Clearview HCG II provides ...
... is based on sequential binding of HCG ... (specific for the *-chain of HCG) immobilized ... for the *-chain of HCG) conjugated to ... step, chromogenic substrate is added and colors ...
... Laboratories offers a comprehensive line of pregnancy ... and urine in convenient one-step stick and ... testing options. Clearview Easy HCG is a ... stick format. Clearview HCG II provides ...
For the quantitative determination of Glycohemoglobin in blood....
Medicine Products: